Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil dose comparison for mortality in adults with pulmonary arterial hypertension
NL-OMON41536Phase 4Active, not recruiting
- Sponsor
- Pfizer
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of sildenafil in pulmonary arterial hypertension (PAH) (3 arms), sponsored by Pfizer. Primary endpoint: Time to death. Started Sep 2014; status: active, not recruiting.
02
Drugs
sildenafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON41536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41536.